



Addendum in print

To cite this article: (2014) Addendum in print, Acta Orthopaedica, 85:1, 2-2, DOI: [10.3109/17453674.2014.885353](https://doi.org/10.3109/17453674.2014.885353)

To link to this article: <https://doi.org/10.3109/17453674.2014.885353>



Copyright: © Nordic Orthopaedic Federation



Published online: 24 Jan 2014.



Submit your article to this journal [↗](#)



Article views: 634



View related articles [↗](#)



View Crossmark data [↗](#)

Addendum in print

Amgen, the producer of denosumab, has warned about the risk of atypical fractures after seeing suspected cases in a long-term trial. No publications on these cases are available. When this editorial was published online in October 2013, the case report by Drampalos et al. (2014) in this issue of Acta Orthopaedica was the first atypical fracture associated with denosumab in the literature indexed in PubMed. In December 2013, another case was published online (Thompson et al. 2013), and a third case has been added to the printed version of this issue (Schilcher and Aspenberg 2014).

Drampalos E, Skarpas G, Barbounakis N, Michos I. Atypical femoral fractures bilaterally in a patient receiving denosumab. A case report. Acta Orthop 2014; 85 (1): 3-5.

Schilcher J, Aspenberg P. Atypical fracture of the femur in a patient using denosumab. A case report. Acta Orthop. 2014; 85 (1): 6-7.

Thompson R N, Armstrong C, Heyburn G. Bilateral atypical femoral fractures in a patient prescribed denosumab – a case report. Bone 2013 Dec 31. pii: S8756-3282(13)00549-8. doi: 10.1016/j.bone.2013.12.027. [Epub ahead of print]